Lapatinib Ditosylate Monohydrate is a pivotal active pharmaceutical ingredient and certified reference standard in the industrial synthesis and quality control of this dual EGFR/HER2 tyrosine kinase inhibitor. The quinazoline core of Lapatinib Ditosylate Monohydrate is constructed through a multi-step synthetic sequence, with a greener four-step route utilizing water and recycled water as reaction media now available. In quality control contexts, Lapatinib Ditosylate Monohydrate and its related impurities—including genotoxic impurities such as 3-chloro-4-[(2-fluorobenzyl)oxy]aniline—are essential analytical reference standards for impurity profiling, analytical method development, and quality control testing.
|
Parameter |
Specification |
|
Product Name |
Lapatinib Ditosylate Monohydrate |
|
CAS Number |
388082-78-8 |
|
Molecular Formula |
C₄₃H₄₄ClFN₄O₁₁S₃ |
|
Molecular Weight |
943.48 g/mol |
|
Appearance |
Light yellow to yellow solid |
For use in combination with capecitabine for the treatment of overexpressed advanced or metastatic breast cancer in patients who have received prior treatment including anthracyclines, paclitaxel, and trastuzumab (Herceptin).
Securing Lapatinib Ditosylate Monohydrate for your manufacturing campaign or analytical program should be straightforward. Cosperpharm makes it simple.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
